Subscribe to our newsletter
The candidate vaccine is the generation of recombinant proteins developed from Sanofi and the generation of complex GSK adjuvants. Sanofi protein-based generation is being used lately to produce a flu vaccine.
The two corporations signed a final agreement following the announcement on July 31 of this year.
The agreement will purchase a Covid-19 vaccine for all Member States of the European Union (EU). The doses reserved will be for low- and middle-income countries.
The initial investment will be provided through the EU for the expansion of Sanofi and GSK production functions in Europe.
Sanofi and GSK’s commercial sites in Belgium, Italy, Germany and France will be used to manufacture antigens and final doses of vaccines for European countries.
Recently, Sanofi and GSK also signed agreements with US governments. But it’s not the first time And the UK to get the vaccine. Both corporations intend to distribute a significant portion of the overall global source to Covax, the ACT-Accelerator vaccine pillar, in 2021/2022. .
Earlier this year, Sanofi and GSK began clinical phase 1/2 of the recombinant protein-based candidate vaccine with Covid-19 adjuvant.
The randomized, double-blind, placebo-controlled trial will evaluate the safety, approximation (tolerability), and immunogenicity (immune response) of the Covid-19 candidate vaccine.
Sanofi is also in the progression of a messenger RNA vaccine (mRNA) in collaboration with Translate Bio, in addition to the recombinant protein vaccine in collaboration with GSK.
Pfizer and BioNTech will supply the EU with two hundred million doses of mRN-based candidate vaccine for SARS-CoV-2
Dissolved oxygen measurement systems
Enter your email so we can contact you.
© PBR 2020. Part of Progressive Trade Media Ltd.